Publication:


abstract

CLIA 88 regulations specify that at least 10% of negative for intraepithelial lesion or malignancy (NILM) Paps be rescreened as a means of quality control (QC). With the incorporation of HPV DNA testing into American Society for Colposcopy and Cervical Pathology guidelines for women ≥30 years of age, a population of NILM patients with positive HPV results exists. slides from this cohort were rescreened to judge the value of Focused QC. Three hundred and eighty-six consecutive, NILM, HCII+, Paps (SurePath and ThinPrep, September 2009 to December 2009) from women aged ≥30 were retrieved from the CellNetix files. These slides were rescreened by cytotechnologists. Slides rescreened as atypical squamous cells (ASC) or higher by cytotechnologists were viewed by cytopathologists (CDS/RJT) who assigned a final interpretation. Of the 386 rescreened cases, 50 (12.9%) were placed in categories of ASC or higher, and 11 (2.9%) were interpreted as LSIL or above. By comparison, routine QC (including random, FocalPoint enriched, and historically high risk cases) was performed on a total of 20,580 Paps (21% of 99,501 annual cases). Concomitant routine QC revealed that 2.1% (427/20,580) were upgraded to ASC or higher and 0.3% (52/20,580) were upgraded to LSIL or higher. Focused rescreening of NILM cases with positive HPV DNA resulted in the detection of approximately ten times more SIL cases than did routine QC Pap slide review at CellNetix. Focused rescreening of this patient set may enhance QC in cytopathology laboratories performing liquid-based Paps. An inherent potential bias in study design is recognized, as results of DNA testing were by definition known at the time of rescreen. Diagn. Cytopathol. 2012; © 2012 Wiley Periodicals, Inc.

Copyright © 2012 Wiley Periodicals, Inc.

Related Articles
The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: I. A prospective intended use study.
Cancer. 1997
The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: I. A prospective intended use study.
Patten SF Jr, Lee JS, Wilbur DC, Bonfiglio TA, Colgan TJ, Richart RM, Cramer H, Moinuddin S. Cancer. 1997 Dec 25; 81(6):337-42.
Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Cancer. 2006
Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Evans MF, Adamson CS, Papillo JL, St John TL, Leiman G, Cooper K. Cancer. 2006 Mar 1; 106(5):1054-64.
Does use of the AutoPap assisted primary screener improve cytologic diagnosis?
Acta Cytol. 1999
Does use of the AutoPap assisted primary screener improve cytologic diagnosis?
Bibbo M, Hawthorne C, Zimmerman B. Acta Cytol. 1999 Jan-Feb; 43(1):23-6.
Review Atypical squamous cells: update on current concepts.
Clin Lab Med. 2003
Review Atypical squamous cells: update on current concepts.
Nayar R, Tabbara SO. Clin Lab Med. 2003 Sep; 23(3):605-32.
Review Screening for cervical cancer: new alternatives and research.
Salud Publica Mex. 2003
Review Screening for cervical cancer: new alternatives and research.
Lörincz AT. Salud Publica Mex. 2003; 45 Suppl 3:S376-87.